OpGen Announces Special Meeting of Stockholders to Vote on Proposed Increase to Number of Authorized Shares of Common Stock
04 November 2021 - 10:30PM
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision
medicine company harnessing the power of molecular diagnostics and
informatics to help combat infectious disease, announced it has
scheduled a Special Meeting of stockholders for December 8, 2021 at
10:00 a.m., Eastern time, to approve its proposed increase of the
number of authorized shares of common stock from 50 million to 100
million and to reduce the stockholder approval requirement for
changes to the Company’s Amended and Restated Certificate of
Incorporation, as amended, to a majority of the outstanding shares
entitled to vote. The proposal to increase the Company’s authorized
shares of common stock and reduce the stockholder approval
requirement is set forth in the Company’s Definitive Proxy
Statement filed with the Securities and Exchange Commission on
October 29, 2021.
Stockholders as of close of business on
October 19, 2021, the record date for the Special Meeting, are
encouraged to vote over the Internet at
http://www.pstvote.com/opgenspecial2021.
Stockholders needing assistance voting or have questions may
contact the Company’s proxy solicitation firm, Alliance Advisors,
LLC, at 800-574-6217 or
melissacarlson@allianceadvisors.com.
About OpGen, Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we
are developing and commercializing molecular microbiology solutions
helping to guide clinicians with more rapid and actionable
information about life threatening infections to improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s product
portfolio includes Unyvero®, Acuitas® AMR Gene Panel and Acuitas®
Lighthouse, and the ARES Technology Platform including ARESdb®,
using NGS technology and AI-powered bioinformatics solutions for
antibiotic response prediction.
For more information, please visit
www.opgen.com.
Forward-Looking Statements
This press release includes statements regarding
the scheduling of OpGen’s Special Meeting. These statements and
other statements regarding OpGen’s future plans and goals
constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and are intended to qualify for the
safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control, and which may cause results to differ materially from
expectations. Factors that could cause our results to differ
materially from those described include, but are not limited to,
our ability to successfully, timely and cost-effectively develop,
seek and obtain regulatory clearance for and commercialize our
product and services offerings, our ability to obtain stockholder
approval for an increase in the Company’s authorized shares of
common stock or otherwise pursue alternative means of continued
financing for its operations, the rate of adoption of our products
and services by hospitals and other healthcare providers, the fact
that we may not effectively use proceeds from recent financings,
the realization of expected benefits of our business combination
transaction with Curetis GmbH, the success of our commercialization
efforts, the impact of COVID-19 on the Company’s operations,
financial results, and commercialization efforts as well as on
capital markets and general economic conditions, the effect on our
business of existing and new regulatory requirements, and other
economic and competitive factors. For a discussion of the most
significant risks and uncertainties associated with OpGen's
business, please review our filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the date of this press release. We undertake no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise.
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Press Contact:Matthew
Bretzius FischTank Marketing and PR
matt@fischtankpr.com
OpGen Investor Contact:Maxwell
ColbertEdison
Group mcolbert@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024